Chinese Study Explores the Psychological Well-being and Health of Dementia Caregivers
A study published in the journal BMC Geriatrics explores the self-assessed well-being of informal care partners and professional caregivers who support people with dementia, such as FTD. The study provides insights that could help guide the development of support tools for improving the overall health of care partners on the FTD journey. Caregiving Can Impact…
Read MoreAFTD Advocacy Webinar: Sharing Your Story to Make a Difference — How to Connect with Legislators and Create Change
Cuts to federal programs are threatening the support systems that people living with FTD and their families rely on. Now more than ever, your voice matters. Join us for a powerful AFTD Advocacy Webinar where you’ll learn how to share your FTD journey with legislators in a way that drives real change. We’ll walk you…
Read More“Alzheimer’s & Dementia” Publishes Summary of AFTD’s 2022 Holloway Summit
Digital health technologies have the potential to benefit the FTD community by improving accessibility to research and clinical care. Such technologies were the focus of the 2022 Holloway Summit — a summary of which was recently published in the journal Alzheimer’s & Dementia. The article highlights several digital health technologies being developed to remotely assess…
Read MoreLeonard A. Lauder, 1933-2025
Leonard A. Lauder, a legend of the cosmetics industry who invested hundreds of millions of dollars into research seeking a cure for FTD and other dementias through his Alzheimer’s Drug Discovery Foundation (ADDF), has died at age 92. AFTD presented Mr. Lauder with the Susan Newhouse & Si Newhouse Award of Hope at our Hope…
Read MoreVesper Bio Clinical Trial for FTD-GRN Treatment Achieves Enrollment Milestone
Danish biotechnology company Vesper Bio announced that it reached a participation milestone in its phase Ib/IIa clinical trial evaluating a treatment for FTD-GRN. Six participants have been enrolled in the study at two sites in Europe. VES001 Supports Progranulin Production by Reducing Degradation of Proteins In FTD caused by inherited mutations of the GRN gene,…
Read MoreAdvancing Hope: Blood Test for Diagnosing Alzheimer’s Disease Approved by FDA
The United States Food and Drug Administration (FDA) approved the marketing of a blood test to diagnose Alzheimer’s disease. The test, known as the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio immunoassay, is intended only for specialized care settings when a person shows signs of cognitive decline. Test Measures Ratio of Alzheimer’s-Related Proteins Along with…
Read More
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)